Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205879 | 1.00 | PPARG (0.53) | PPARGLMNANFE2L2PTGS2PTGS1 | |
| SCHEMBL29175487 | 0.98 | PPARG (0.52) | PPARGLMNANFE2L2PTGS2PTGS1 | |
| SCHEMBL29026002 | 0.98 | PPARG (0.52) | PPARGLMNANFE2L2PTGS2PTGS1 | |
| SCHEMBL5766149 | 0.98 | PPARG (0.52) | PPARGLMNANFE2L2PTGS2PTGS1 | |
| SCHEMBL5766143 | 0.98 | PPARG (0.52) | PPARGLMNANFE2L2PTGS2PTGS1 | |
| SCHEMBL11539912 | 0.87 | PTGES2 (0.50) | PPARGLMNANFE2L2PTGS2PTGS1 | |
| SCHEMBL1194569 | 0.80 | PPARG (0.57) | PPARGLMNANFE2L2PTGES2MAOB | |
| SCHEMBL19155588 | 0.80 | PPARG (0.57) | PPARGLMNANFE2L2PTGES2MAOB | |
| SCHEMBL587895 | 0.80 | PPARG (0.57) | PPARGLMNANFE2L2PTGES2MAOB | |
| SCHEMBL3730162 | 0.80 | PPARG (0.57) | PPARGLMNANFE2L2PTGES2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773310-B9 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2012-04-25 | — | — | EP | claimed |
| EP-1773310-B1 | ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFONAMIDES AND ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-10-19 | — | — | EP | claimed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | claimed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | claimed |
| JP-58090556-A | — | — | None | — | — | JP | disclosed |
| EP-3057981-B1 | THERAPEUTIC CANCER VACCINE BASED ON STRESS PROTEINS RENDERED IMMUNOGENIC | BRENUS PHARMA (FR) | 2021-11-10 | — | — | EP | disclosed |
| US-20210207175-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-07-08 | — | — | US | disclosed |
| EP-3825409-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-05-26 | — | — | EP | disclosed |
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-10689354-B2 | Aminoazole derivative | TEIJIN PHARMA LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| WO-2019238091-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | 中国科学院上海有机化学研究所 | 2019-12-19 | — | — | WO | disclosed |
| US-10392348-B2 | 2-oxo-3,4-dihydroquinoline compounds as plant growth regulators | SYNGENTA PARTICIPATIONS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0467621-B1 | N-phenyl-N'-alkylsulfonylureas, process for their preparation and antitumor compositions containing them | LILLY CO ELI (US) | 1994-06-15 | — | — | EP | disclosed |
| US-5216026-A | Administering to the mammal N-1-butanesulfonamide derivatives and salts | ELI LILLY AND COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0467621-A1 | N-phenyl-N'-alkylsulfonylureas, process for their preparation and antitumor compositions containing them | ELI LILLY AND COMPANY (US) | 1992-01-22 | — | — | EP | disclosed |
| JP-S5890556-A | BENZAMIDE DERIVATIVE AND HERBICIDE CONTAINING THE SAME | ISHIHARA SANGYO KAISHA LTD | 1983-05-30 | — | — | JP | disclosed |
| US-4136180-A | HYPOLIPIDEMIC SUBSTITUTED STYRENESULFONYLUREAS | PFIZER INC. (US) | 1979-01-23 | — | — | US | disclosed |
| US-4062960-A | Hypolipidemic alkenesulfonamides | PFIZER INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-3983107-A | ARTERIOSCLEROSIS | PFIZER INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392348-B2 | 2-oxo-3,4-dihydroquinoline compounds as plant growth regulators | CDC25B, OSR1, CDC25C | PPARG 599/4885LMNA 4460/4885NFE2L2 4/4885 |
| US-10689354-B2 | Aminoazole derivative | AR, NR3C2, NR5A1 | PPARG 410/4885LMNA 3465/4885NFE2L2 3325/4885 |
| US-20210207175-A1 | COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF | TET2, ZFX, ZFR | PPARG 334/4885LMNA 1544/4885NFE2L2 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.